GlassScriptPhysician profile
Per L Okey
NPI 1518059765
$2,031.04
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $346 · 2021: $736 · 2022: $287.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $332.75 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.10 | 2019-2021 | |
| Allergan, INC. | $169.74 | 2019-2020 | |
| Abbvie INC. | $149.03 | 2021-2022 | |
| Novo Nordisk INC | $143.23 | 2019-2022 | |
| Lilly USA, LLC | $134.73 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.95 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $87.83 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $84.78 | 2021 | |
| Novartis Pharmaceuticals Corporation | $82.72 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.97 | 2022 | |
| Pfizer INC. | $67.34 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $59.02 | 2020-2022 | |
| Alkermes, INC. | $57.52 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $54.52 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $45.74 | 2019-2021 | |
| Eisai INC. | $34.32 | 2021 | |
| Indivior INC. | $34.03 | 2019-2020 | |
| Glaxosmithkline, LLC. | $28.65 | 2019-2022 | |
| Mylan Specialty L.P. | $23.65 | 2021 | |
| Amgen INC. | $18.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.03 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.24 | 2021 | |
| Orexo US, INC. | $13.22 | 2019 |
Research and ownership
$150.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Per Okey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.